FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Dolan Christine (Last) (First) (Middle)						2. Issuer Name and Ticker or Trading Symbol MARAVAI LIFESCIENCES HOLDINGS, INC. [MRVI] 3. Date of Earliest Transaction (Month/Day/Year) 01/25/2022								tionship of F all applicab Director Officer (g below)	ive title	, 10% Owne			
C/O MARAVAI LIFESCIENCES HOLDINGS, INC. 10770 WATERIDGE CIRCLE, SUITE 200 (Street) SAN DIEGO CA 92121 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Т	able I - Noi	n-Deriv	ative S	ecuritie	s Acq	uired,	Disp	osed of	f, or l	Benefic	cially Ow	ned					
1. Title of Security (Instr. 3) 2. Tra				2. Transa Date (Month/D		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an				5. Amount Securities Beneficially Following	y Owned Reported	Form	nership : Direct (D) lirect (I) . 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	Amount (A)		(A) or (D)	Price	(Instr. 3 and 4)				(11150.4)					
Class A Common Stock 04					0/2021			A	V ⁽¹⁾	916		A	\$22.95	916			D		
Class A Common Stock 10/3					31/2021			A	V ⁽¹⁾	203		Α	\$22.95	1,119			D		
Class A Common Stock 01/				01/25	/2022			A		17,00	17,000 A		(2)	18,119			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun Securities Underly Derivative Security 3 and 4)		ing Derivative		er of e s ally g I ion(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	e V	(A)	(D)	Date Expiration Exercisable Date Title Amount or Number of Shares			(Instr. 4)								
Employee Stock Option (Right to Buy)	\$26.32	01/25/2022		A		31,500		(3)		01/25/2032	Co	lass A mmon	31,500	\$0.00	31,50	00	D		

Explanation of Responses:

- 1. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 1,119 shares of Class A Common Stock was also exempt pursuant to Rule 16b-3(c).
- 2. Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the Reporting Person's continued employment with the Issuer.
- 3. Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on March 15, 2022 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

Chief Operating Officer, Biologics Safety Training

/s/ Kurt Oreshack, by power of attorney for Christine Dolan

01/27/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.